A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer

AAPS Journal

Volumn 16, Issue 6, 2014, Pages 1194-1203

  Gross, Brett P ^a,b   Wongrakpanich, Amaraporn ^a   Francis, Meghan B ^c   Salem, Aliasger K ^a,b   Norian, Lyse A ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Breast cancer; Microparticle; PLGA; Tumor lysate; Vaccine

Indexed keywords

CANCER VACCINE; DRUG CARRIER; IMMUNOLOGICAL ADJUVANT; LUCIFERASE; POLYGLACTIN MICROPARTICLE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9; TUMOR LYSATE VACCINE; UNCLASSIFIED DRUG; BIOMATERIAL; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BIOLUMINESCENCE; BREAST CANCER; CANCER GROWTH; CANCER IMMUNIZATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; IN VIVO STUDY; LUNG HOMOGENATE; LUNG METASTASIS; LYMPH NODE; METASTASIS INHIBITION; MICROENCAPSULATION; MOUSE; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEPTOR UPREGULATION; TREATMENT DURATION; TUMOR VOLUME; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CD8+ T LYMPHOCYTE; CHEMISTRY; DRUG EFFECTS; DRUG FORMULATION; IMMUNOLOGY; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; PATHOLOGY; REGULATORY T LYMPHOCYTE; SECONDARY; TUMOR CELL LINE; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; AUTOIMMUNITY; BIOCOMPATIBLE MATERIALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; LACTIC ACID; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, INBRED BALB C; PARTICLE SIZE; POLYGLYCOLIC ACID; T-LYMPHOCYTES, REGULATORY; VACCINATION;

EID: 84938807240     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-014-9662-z     Document Type: Article

References (38)

1. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA: Cancer J Clin. 2014;64(1):52–62.
2. Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC. Past, present, and future challenges in breast cancer treatment. J Clin Oncol: Off J Am Soc Clin Oncol. 2014;32(19):1979–86.
3. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1–22.
4. Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med. 2008;14(6):623–8.
5. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature. 2006;440(7085):808–12.
6. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801.
7. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature. 2006;440(7086):890–5.
8. Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M, et al. Type I IFNs control antigen retention and survival of CD8alpha(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol. 2011;186(9):5142–50.
9. Platt AM, Randolph GJ. Dendritic cell migration through the lymphatic vasculature to lymph nodes. Adv Immunol. 2013;120:51–68.
10. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.
11. Joshi VB, Geary SM, Gross BP, Wongrakpanich A, Norian LA, Salem AK. Tumor lysate-loaded biodegradable microparticles as cancer vaccines. Expert Rev Vaccines. 2014;13(1):9–15.
12. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29(36):4828–36.
13. Prasad S, Cody V, Saucier-Sawyer JK, Saltzman WM, Sasaki CT, Edelson RL, et al. Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. Nanomed: Nanotechnol, Biol, Med. 2011;7(1):1–10.
14. Hanlon DJ, Aldo PB, Devine L, Alvero AB, Engberg AK, Edelson R, et al. Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen. Am J Reprod Immunol. 2011;65(6):597–609.
15. Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA. Polymeric particles in vaccine delivery. Curr Opin Microbiol. 2010;13(1):106–12.
16. Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine delivery systems: size matters. AAPS J. 2013;15(1):85–94.
17. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Current protocols in immunology. Edited by John E Coligan [et al]. 2001; Chapter 20: Unit 20 2.
18. Weigelt B, Peterse JL, van’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591–602.
19. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992;52(6):1399–405.
20. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008;38(5):1404–13.
21. Roederer M. Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats. Cytometry. 2001;45(3):194–205.
22. Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM, et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest. 2010;120(2):607–16.
23. Pham NL, Pewe LL, Fleenor CJ, Langlois RA, Legge KL, Badovinac VP, et al. Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly. Proc Natl Acad Sci U S A. 2010;107(27):12198–203.
24. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, et al. Autoimmunity associated with immunotherapy of cancer. Blood. 2011;118(3):499–509.
25. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res: Off J Am Assoc Cancer Res. 2003;9(3):998–1008.
26. Corbiere V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethe B, et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 2011;71(4):1253–62.
27. Sun H, Pollock KG, Brewer JM. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine. 2003;21(9–10):849–55.
28. Yoshida M, Babensee JE. Poly(lactic-co-glycolic acid) enhances maturation of human monocyte-derived dendritic cells. J Biomed Mat Res Part A. 2004;71(1):45–54.
29. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P, et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology. 2006;117(1):78–88.
30. Watanabe S, Deguchi K, Zheng R, Tamai H, Wang LX, Cohen PA, et al. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J Immunol. 2008;181(5):3291–300.
31. Fujita T, Teramoto K, Ozaki Y, Hanaoka J, Tezuka N, Itoh Y, et al. Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types. Cancer Res. 2009;69(12):5142–50.
32. Deng L, Zhang H, Luan Y, Zhang J, Xing Q, Dong S, et al. Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin Cancer Res: Off J Am Assoc Cancer Res. 2010;16(16):4105–12.
33. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005;175(9):6169–76.
34. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.
35. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res. 1988;48(6):1671–5.
36. Xing Y, Hogquist KA. T-cell tolerance: and peripheral. Cold Spring Harbor perspectives in biology. 2012;4(6).
37. Neller MA, Lopez JA, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol. 2008;20(5):286–95.
38. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release: Off J Control Release Soc. 2010;148(2):135–46.